MB-111 / Mammoth Biosciences - LARVOL DELTA

Mammoth Biosciences Announces Nomination of MB-111 as First Development Candidate and Appoints Genetic Medicines Veteran Bob D. Brown to Board of Directors (Businesswire) - "Mammoth Biosciences...today announced the nomination of its first clinical development candidate, MB-111....MB-111 has the potential to be a first-in-class, one-time treatment for patients with very high triglycerides including familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG)....These patients suffer from recurrent episodes of acute pancreatitis, leading to frequent hospitalizations, as well as an increased risk of cardiovascular disease. Mammoth Biosciences is on track to initiate IND-enabling studies this year....'The preclinical data on MB-111 is compelling, and we’re excited about its potential to be a first-in-class genetic cure for debilitating diseases such as FCS and SHTG.'"

Preclinical • Familial Chylomicronemia Syndrome • Severe Hypertriglyceridemia